Everolimus vs. temsirolimus for advanced renal cell carcinoma: Use and use of resources in the US Oncology Network

Clinical Genitourinary Cancer

Volumn 11, Issue 2, 2013, Pages 115-120

  Vogelzang, Nicholas J ^a   Bhor, Menaka ^b   Liu, Zhimei ^c   Dhanda, Rahul ^b   Hutson, Thomas E ^d  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b McKesson Specialty Health   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Guidelines; Kidney; mTOR; Resource use

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EMERGENCY CARE; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; GUIDELINE ADHERENCE; HUMANS; KIDNEY NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84876988997     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.09.008     Document Type: Article

References (24)

1. M. Sun, R. Thuret, F. Abdollah Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis Eur Urol 59 2011 135 141
2. P.T. Scardino, W.M. Linehan, M.J. Zelefsky et al. Comprehensive Textbook of Genitourinary Oncology 4th Edition 2011 Lippincott Williams & Wilkins Philadelphia, PA
3. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
4. S.K. Pal, S. Williams, D.Y. Josephson Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm Mol Cancer Ther 11 2012 526 537
5. F. Zustovich, G. Lombardi, O. Nicoletto Second-line therapy for refractory renal-cell carcinoma Crit Rev Oncol Hematol 83 2012 112 122
6. S.K. Pal, N.J. Vogelzang Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS Clin Genitourin Cancer 9 2011 3 5
7. N.J. Vogelzang Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol 28 2010 5017 5019
8. T.E. Hutson Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence Oncologist 16 suppl 2 2011 14 22
9. C.N. Sternberg, I.D. Davis, J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
10. B.I. Rini, B. Escudier, P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
11. B. Escudier, A. Pluzanska, P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
12. G. Hudes, M. Carducci, P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
13. G.R. Hudes, A. Berkenblit, J. Feingold Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma Semin Oncol 36 suppl 3 2009 S26 S36
14. R.J. Motzer, B. Escudier, S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
15. G.R. Hudes, M.A. Carducci, T.K. Choueiri NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy J Natl Compr Canc Netw 9 suppl 1 2011 S1 S29
16. R.J. Motzer, B. Escudier, S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
17. M.M. Oken, R.H. Creech, D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
18. R.T. Tripathi, L.K. Heilbrun, V. Jain Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma Urology 68 2006 296 301
19. D. Shek, B. Tomlinson, M. Brown Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients Clin Genitourin Cancer 10 2012 93 98 [Epub 2012 Feb 28]
20. D. Pascual, A. Borque Epidemiology of kidney cancer Adv Urol 2008 782381 [Epub 2008 Nov 4]
21. V.D. Ferrari, G. Fogazzi, F. Valcamonico III-IV line of target therapy in advanced renal cell carcinoma (RCC) J Clin Oncol 28 suppl 2010 abstract e15148
22. R.J. Amato, J. Jac, S. Giessinger A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer Cancer 115 2009 2438 2446
23. G. Sonpavde, T.K. Choueiri, B. Escudier Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 61 2012 307 316
24. Hutson TE. Temsirolimus vs. sorafenib as second line therapy in metastatic renal cell carcinoma: Results from the INTORSECT trial. LBA22-PR. Presented at Proffered Paper session Renal Cancer at 2012 European Society for Medical Oncology ESMO, Vienna, Austria, September 28, 2012 to October 2, 2012.